Cargando…

System analysis based on the cancer–immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma

BACKGROUND: Immune checkpoint inhibitors as monotherapies for advanced hepatocellular carcinoma (HCC) fail to achieve satisfying results, while combination therapies show greater efficacy. Therefore, identifying new combined targets for immune checkpoint inhibitors could be promising. METHODS: We co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xu, Zhou, Tao, Chen, Xingyi, Wang, Yu, Ding, Yushi, Tu, Haoyang, Gao, Shengyang, Wang, Haoyu, Tang, Xinying, Yang, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900045/ https://www.ncbi.nlm.nih.gov/pubmed/35246476 http://dx.doi.org/10.1136/jitc-2021-004414

Ejemplares similares

Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
por: Bao, Xuanwen, et al.
Publicado: (2020)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Combinatorial immunotherapy induces tumor-infiltrating CD8(+) T cells with distinct functional, migratory, and stem-like properties
por: Van Braeckel-Budimir, Natalija, et al.
Publicado: (2021)

2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis
por: Pan, Banglun, et al.
Publicado: (2023)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

Quantifying the impact of immunotherapy on RNA dynamics in cancer
por: Usaite, Ieva, et al.
Publicado: (2023)

Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy
por: Nagaoka, Koji, et al.
Publicado: (2020)

Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
por: Boelaars, Kelly, et al.
Publicado: (2023)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

Implication of (99m)Tc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells
por: Gao, Yu, et al.
Publicado: (2023)

GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma
por: Wang, Zhaowei, et al.
Publicado: (2021)

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020)

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023)

Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies
por: Odunsi, Adekunle, et al.
Publicado: (2020)

Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy
por: Beyranvand Nejad, Elham, et al.
Publicado: (2020)

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
por: Lopes, Jared E, et al.
Publicado: (2020)

An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy
por: Wang, Hui, et al.
Publicado: (2020)

Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3
por: Zhou, Zhengjun, et al.
Publicado: (2021)

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
por: Beyranvand Nejad, Elham, et al.
Publicado: (2021)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

Neoantigens as potential vaccines in hepatocellular carcinoma
por: Repáraz, David, et al.
Publicado: (2022)

2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1
por: Chen, Zhanfei, et al.
Publicado: (2020)

Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
por: Cubas, Rafael, et al.
Publicado: (2020)

Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4
por: Marshall, Lisa A, et al.
Publicado: (2020)

PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy
por: Choudhury, Ruhul H, et al.
Publicado: (2022)

Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
por: Krieg, Carsten, et al.
Publicado: (2022)

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
por: Marcu, Ana, et al.
Publicado: (2021)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
por: Liu, Hsin-Yu, et al.
Publicado: (2021)

Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
por: Zhu, Lin, et al.
Publicado: (2022)

Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma
por: Tang, Weiwei, et al.
Publicado: (2023)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
por: Lo, Amy A, et al.
Publicado: (2021)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy
por: van Elsas, Marit J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l0h11dnroj1aqrtpcns7sds6e2